Pharmaceutical Business review

Actavis wins FDA approval for generic seizure drug

Levetiracetam oral solution is available in the 100mg/ml strength and is the generic equivalent of Keppra oral solution by UCB. Levetiracetam oral solution is used in the treatment of partial onset seizures in adults and children with epilepsy.

Doug Boothe, CEO of Actavis in the US, said: “The approval of levetiracetam oral solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms.”